Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Common Equity (2020 - 2026)

Cardiol Therapeutics filings provide 3 years of Common Equity readings, the most recent being $38.5 million for Q4 2022.

  • On a quarterly basis, Common Equity fell 36.42% to $38.5 million in Q4 2022 year-over-year; TTM through Dec 2022 was $38.5 million, a 36.42% decrease, with the full-year FY2022 number at $38.5 million, down 36.42% from a year prior.
  • Common Equity hit $38.5 million in Q4 2022 for Cardiol Therapeutics, down from $45.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $60.5 million in Q4 2021 to a low of $10.2 million in Q4 2020.
  • Median Common Equity over the past 3 years was $41.7 million (2022), compared with a mean of $38.6 million.
  • Biggest five-year swings in Common Equity: surged 494.18% in 2021 and later crashed 36.42% in 2022.
  • Cardiol Therapeutics' Common Equity stood at $10.2 million in 2020, then soared by 494.18% to $60.5 million in 2021, then crashed by 36.42% to $38.5 million in 2022.
  • The last three reported values for Common Equity were $38.5 million (Q4 2022), $45.0 million (Q3 2022), and $49.3 million (Q2 2022) per Business Quant data.